Start the conversation
We get a lot of feedback from all of you here at Private Briefing and we try to answer as many queries as we can - through our great customer service team, in direct responses or by addressing them in "update" columns.
Some questions are just so good that we have to single them out - like one I just received from subscriber Torben R.
"Bill, it looks like biotech recommendation Pharmacyclics Inc. (Nasdaq: PCYC) is trying to break down through the 200-day moving average. Is this a cause for concern?" - Torben R.
This is a great question.
This is premium content for Private Briefing subscribers only.